secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001437749-24-021220
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica raises $11.8M in private placement at $2.50/share; funds stroke and preeclampsia trials
--------------------------------------------------------------------------------

- Gross proceeds $11.8M from sale of 4.72M shares at $2.50/share; expected close June 28, 2024.
- Net proceeds to fund DM199 phase 2/3 ReMEDy2 trial for acute ischemic stroke and expansion into preeclampsia.
- Cash runway extended into Q3 2026.
- Non-management related parties committed $6.0M (2.4M shares); exempt from MI 61-101 valuation and minority approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924021220/0001437749-24-021220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924021220/dmtp20240625_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-021220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer